| Ren, Xiubao |
NCT04619433: A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC. |
|
|
| Recruiting | 3 | 560 | RoW | Camrelizumab;Pemetrexed and Carboplatin; Famitinib;, SHR1210, Camrelizumab;Pemetrexed and Carboplatin;Placebo | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous Non-small-cell Lung Cancer | 12/22 | 10/23 | | |
TQB2450-III-07, NCT04523272: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer |
|
|
| Active, not recruiting | 3 | 528 | RoW | TQB2450, Anlotinib, Sunitinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Renal Cancer | 06/25 | 12/25 | | |
NCT03950154: Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer |
|
|
| Recruiting | 3 | 198 | RoW | Bevacizumab Injection [Avastin], Avastin, Oxaliplatin, Capecitabine, PD1-T cells, PD-1 monoclonal antibody-activated peripheral blood T-lymphocyte | Tianjin Medical University Cancer Institute and Hospital | Colorectal Cancer | 08/23 | 08/23 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
NCT06704620: Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 430 | RoW | Diphenhydramine, Tislelizumab, Pemetrexed, Albumin paclitaxel, Carboplatin, Cisplatin | Tianjin Medical University Cancer Institute and Hospital | Advanced and Metastatic NSCLC | 11/26 | 11/27 | | |
NCT05420324: A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma |
|
|
| Completed | 2 | 20 | RoW | YH003, Pembrolizumab, albumin paclitaxel | Eucure (Beijing) Biopharma Co., Ltd | Mucosal Melanoma | 03/24 | 03/24 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
NCT05405439: To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer |
|
|
| Terminated | 1/2 | 39 | RoW | TQB3823 tablets, Abiraterone acetate tablets, prednisone acetate tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Metastatic Castration-resistant Prostate Cancer | 07/23 | 07/23 | | |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
NCT05767866: Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR |
|
|
| Recruiting | 1/2 | 160 | RoW | YK-029A | Suzhou Puhe Pharmaceutical Technology Co., LTD | Treatment, Treatment Side Effects | 12/23 | 05/24 | | |
NCT05341557: A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma |
|
|
| Recruiting | 1 | 110 | RoW | BPI-371153 | Betta Pharmaceuticals Co., Ltd. | Advanced Solid Tumor, Lymphoma, NSCLC, HCC | 12/26 | 04/27 | | |
NCT05430373: GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors |
|
|
| Recruiting | 1 | 31 | RoW | GT101 | Grit Biotechnology | Solid Tumors, Adult | 08/25 | 12/25 | | |
| Recruiting | N/A | 1500 | RoW | PD-1 and PD-L1 inhibitor, Targeted drugs, chemotherapy drugs | Tianjin Medical University Cancer Institute and Hospital | Immune-related Adverse Event, Malignant Solid Tumors, Acute Leukemia, Serum Ferritin | 07/26 | 07/27 | | |
